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Series on pragmatic trials
Pragmatic trials aim to generate real world evidence on the (relative) effects of treatments, generalizable to routine practice. In this series we will discuss options and choices for pragmatic trial design, operational consequences and the interpretation of results. Data analysis according to the intention-to-treat principle is recommended, and crossover between 31 treatment arms and strong treatment preferences may be accounted for in the study design in specific 32 situations. Although usual care is the comparator of choice, this may differ substantially between 33 centres and countries complicating comparator choice. Using clinical guidelines to define usual care can 34 be helpful in standardizing comparator treatments, however, this may decrease the applicability of the 35 results to real life settings. Conversely, using multiple usual care treatment arms will increase the 36 complexity of the study. The specific objectives of the trial and design choices should be discussed with 37 all stakeholders to realize the full potential of the pragmatic trial. • In this paper we discuss the operational and methodological challenges in pragmatic trials 45 related to defining and comparing treatment strategies and the choice of suitable 46 comparator(s). 47
• The research question determines whether new treatments are started or an existing treatment 48 is continued, whether treatment switches between arms are allowed, and whether a superiority 49 or non-inferiority design is more appropriate. 50
• Treatment strategies should resemble routine care as closely as possible, including dosing, co-51 medication and the supply and reimbursement of drugs. 52
• Usual care is the comparator of choice for pragmatic trials but implementation may be difficult if 53 usual care differs between centres or countries. 54 New drugs are typically examined for their efficacy and safety in randomized clinical trials (RCTs), under 58 strictly controlled conditions in highly selected patient groups. If the results obtained by these 59 explanatory trials do not reflect treatment effects in patients seen in day-to-day clinical practice, they 60 cannot adequately guide physicians' treatment decisions [1, 2] . Pragmatic trials can deliver real-world 61 evidence (RWE) on the value of new treatments compared to usual care [1, 3] . When executed well 62 pragmatic trials maintain the strength of an RCT but also generate results that are applicable to the 63 usual care setting. 64
Treatment related study procedures in pragmatic trials should not change routine clinical practice. 65
Decisions on drug dosage, co-interventions, and the management of adverse effects are therefore left to 66 the physician [1] . Placebos and other methods of blinding patients and physicians for the assigned 67 treatment group are generally not used in pragmatic trials, as knowledge of the treatment status, and 68 expectations or behaviour changes associated with that knowledge are part of the treatment effect in 69 real life. Also, any measures taken to promote treatment adherence should reflect usual practice [4] . 70
The focus therefore is on comparing the effectiveness of treatment strategies rather than on the 71 efficacy of single compounds [5] . 
Research questions and comparisons 86
A treatment in routine clinical practice can be compared to usual care in several ways in a pragmatic 87 trial, depending on the question that is addressed. For example, patients with well-controlled type 2 88 diabetes using oral antidiabetic medication can be randomly assigned to either switching to a new 89 treatment or to continuing their current treatment. This would address a first question of whether the 90 new treatment has advantages over usual care with regard to adverse effects, costs, convenience, or the 91 control of body weight while maintaining glycaemic control. If the new treatment is expected to have 92 certain advantages but equal effectiveness a non-inferiority design may be appropriate [8] . 93
Alternatively, for patients whose blood sugar is not well-controlled a second question arises, namely 94 whether blood sugar control could be improved with a new treatment. In this case, either the new 95 treatment could be compared to continuation of the current treatment, or different new treatments can 96 be compared. Thirdly, newly diagnosed patients may be randomised to a treatment recommended by 97 current guidelines or a new treatment strategy. Depending on the research question and characteristics 98 of treatments, non-inferiority or superiority designs may be appropriate in the latter two situations. 99
It is essential to define the question a pragmatic trial is supposed to answer. The question will 100 inform the design choices and determine how investigators deal with switches (crossovers) to the 101 treatment in the other trial arm (see "Dealing with switches", below and Table 1 ). The first question 102 above may be the easiest to address from an operational perspective because eligible patients can
readily be identified among a pool of patients with type 2 diabetes; but trial results will not be 104 applicable to patients newly diagnosed with diabetes. A challenge of questions demanding a non-105 inferiority design is that generally more patients are needed for such a design [8] . or countries [13] . In these situations the applicability to a centre or region has to be weighed against 120 wider generalizability of results to a country or countries. In trials with a long duration, usual care may 121 change during the conduct of a trial, for example due to changes in reimbursement or a new medication 122 that becomes available on the market. In this situation changes in usual care in newly recruited patients, 123 or switches to a new usual care regimen in enrolled patients may be appropriate to continuously reflect 124 routine clinical practice.
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appropriate choices may exist [14] . Different usual care options may be included as separate arms but 130 this will increase complexity and costs, and physicians may object to (some of) the options [13, 15] . 131
Alternatively, different usual care options may be combined into one comparator arm with the choice of 132 treatment left to the physician. Although this approach may follow usual practice most closely, the 133 results might be applicable to a smaller number of settings with a similar mix of usual care options. Also, 134 the estimates of relative effectiveness compared to a mix of usual care options may be more relevant to 135 policymakers than to clinicians whose primary interest is to find the best treatment for individual 136 patients. In general, in pragmatic trials clinical investigators will less likely be faced with a conflict of 137 duties (strict adherence to study protocol versus provision of optimal patient care) [18] than in other 138 trials, for example placebo-controlled trials, because pragmatic trials mimic routine clinical care. 
Random allocation 160
The random allocation of patients to treatments aims to reduce confounding due to differences in 161 prognostic variables that may be present between treatment arms. A computer algorithm generates the 162 allocation sequence and this sequence is concealed from those enrolling patients since knowledge of the 163 allocation might influence enrolment and lead to groups that differ in prognostic factors [21, 22] . The 164 randomization process can be challenging for routine care sites that are unfamiliar with clinical research 165
[23]. Web -based randomization procedures that assign patients to groups after assessing eligibility and 166 recording informed consent are most suitable for pragmatic trials in routine care settings [23, 24] . 167 168
Level of randomization 169
In RCTs patients are typically individually assigned to treatment groups. However, in some situations the 170 randomization of groups or units such as general or specialist practices or hospitals may be preferable. trial. However, physicians may find this challenging with new medications where there is no or limited 230 experience regarding dose-adjustments and co-medications, for example pre-launch. Especially with a 231 real-life population it is more likely that subgroups (i.e. based on age or severity of the disease) require 232 different doses of a drug [38] . In this situation clinicians will need guidance based on the best available 233 evidence, which may come from smaller (phase II) trials. 234 235
Data analysis 236
In any pragmatic trial the data should be analysed according to the intention-to-treat principle which 237 stipulates that comparisons are according to the originally randomized groups. Other analyses, including 238 per-protocol analyses or analyses censoring follow-up at the time of switching will tend to be biased 239
[39]. Patients who switch and those who use co-medication will often differ from those who do not with 240 Table 1 
. Questions, comparisons, and treatment switches that should be allowed in pragmatic trials

Question Comparisons Switches
Should the new drug be approved and made available? • The comparator should be the reference treatment according to up-to-date high-quality clinical practice guidelines at European or international level. If no such guidelines exist, evidence is required that the chosen comparator intervention is routinely used in clinical practice.
• Evidence that the intervention is used in routine clinical care could come, in order of preference, • Pharmaceuticals have to be optimally dosed or scheduled in line with marketing authorization or high-quality clinical practice guidelines.
• Where patient subpopulations are considered, for example according to disease severity, lines of treatment, stages of disease, or genetic characteristics, additional comparators may need to be included.
• The most appropriate comparators should be identified before the assessment begins or in the early phase of an assessment.
Adapted from EUnetHTA methodological guideline for relative effectiveness assessment (REA) of pharmaceuticals [9] .
